Lotte Biologics kicks off ADC service at Syracuse plant
The deal represents the first major milestone in launching full-scale operations at the company's ADC manufacturing facility, located at the Syracuse Bio Campus in the US state of New York, an expansion project that began in 2023.
Through the contract, Lotte Biologics is officially introducing its ADC contract development and manufacturing services, tailored to support clients across all stages, from clinical trials to commercial-scale production.
"With this contract as a starting point, we will ensure a stable supply of high-quality ADC therapeutics and solidify our position in the global market, not only as an antibody manufacturer, but also as a CDMO specializing in ADCs,' Lotte Biologics CEO James Park said. 'We also plan to actively pursue partnerships to further strengthen our competitiveness in the ADC modality business."
Lotte Biologics will continue to seek new clients and expand its collaborative efforts, aiming to provide integrated, one-stop solutions for ADC development and production, the firm said.
Developed with an investment of around $100 million, Lotte Biologics' ADC facility meets the current Good Manufacturing Practices of the US Food and Drug Administration and delivers comprehensive end-to-end manufacturing services.
The facility includes a fully integrated production and purification system, featuring a conjugation reactor capable of handling up to 1,000 liters. It also offers in-house quality control testing and advanced analytical characterization services.
Additionally, the site is outfitted with a single-use system that supports the entire workflow — from antibody preprocessing to the automated aseptic filling of drug substances — allowing for flexible and efficient service tailored to diverse client requirements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
Trina Storage Enhances Smart Manufacturing to Strengthen Global Delivery Capabilities
CHUZHOU, China, Aug. 20, 2025 /PRNewswire/ -- Trina Storage, a leading global energy storage solution provider, has recently announced the completion of a major upgrade to its smart integration factory in Chuzhou, China. The upgraded facility strengthens the company's intelligent manufacturing capabilities and system integration capacity, enabling faster, more efficient, and higher-quality delivery of utility-scale energy storage systems to customers around the world. As global demand for energy storage accelerates, Trina Storage is scaling up its production capacity while enhancing the performance, flexibility, and traceability of its manufacturing processes. The recent upgrade focuses on end-to-end automation and digitalization across core processes, from cell production and module assembly to containerized system integration and testing. The level of automation at the Chuzhou factory has increased by 23%, while overall production efficiency has improved by 50%, and testing speed by more than 60%, significantly boosting the factory's ability to meet large-scale project, high-standard project requirements. Digital systems have also been fully integrated into the factory's infrastructure. Supported by industrial IoT platforms, the facility now enables real-time data flow and intelligent coordination across key functions such as production, logistics, and quality assurance. Integration of Enterprise Resource Planning (ERP) and Manufacturing Execution Systems (MES) further enhances visibility and agility in daily operations. To ensure consistent product quality and safety, the factory also implements a robust traceability framework covering process design, equipment maintenance, energy use, and logistics. This enables full product tracking and early risk detection, reinforcing safety and reliability at every stage. Trina Storage's energy storage systems have been deployed across key markets worldwide, with cumulative shipments surpassing 10 GWh by the end of 2024. In 2025, annual shipments are projected to reach 8–10GWh. Backed by 16 GWh of current production capacity and a planned scale-up to 25 GWh by the end of 2025, Trina Storage continues to build global delivery capabilities that align with the accelerating demand for clean and reliable energy storage solutions. "The smart integration factory upgrade represents more than just a technological enhancement," said Ni Lili, Global Product President of Trinasolar. "It reflects our long-term commitment to innovation, quality, and delivering customer value at scale. As we continue to invest in manufacturing excellence and global infrastructure, we remain focused on supporting the rapid adoption of energy storage worldwide through safe, intelligent, and high-performance solutions."
Korea Herald
31-07-2025
- Korea Herald
Daewoong's Nabota hits record H1 sales, expands to Middle East
South Korean drugmaker Daewoong Pharmaceutical announced Thursday that its botulinum toxin product, Nabota, posted 115.4 billion won ($83 million) in revenue in the first half of this year, up 28 percent from last year. With this growth, Daewoong expects to surpass 200 billion won in annual sales this year. Nabota was approved by the US Food and Drug Administration in 2019 as the first Asian botulinum toxin. Since then, Daewoong has pursued a premium strategy focused on high purity, high safety and strict quality control standards. Nabota is now sold under the brand name Jeuveau in the US, the world's largest aesthetics toxin market, where it holds a 14 percent market share in the aesthetics segment, ranking second overall. Daewoong also continues to grow in Latin America and Southeast Asia, following major deals previously signed in Brazil and Thailand. The company recently signed a deal with Kuwait, expanding its reach to five Middle Eastern countries, including the UAE, Saudi Arabia and Qatar — the widest regional coverage among Korean toxin brands. Alongside product expansion, Daewoong is promoting its proprietary injection technique, Nabolift, through global training programs, aiming to enhance medical outcomes and brand presence. 'Nabota is now a global top-tier brand in aesthetics,' said Yoon Joon-soo, head of Daewoong Pharmaceutical's Nabota Business Division. 'We will strengthen our global leadership with premium quality and scientific proof.'
Korea Herald
28-07-2025
- Korea Herald
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate) Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH) Abstract Number: 2907 Presentation Number: 2113P Date: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:
